Rhumbline Advisers Chemomab Therapeutics Ltd. Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
A detailed history of Rhumbline Advisers transactions in Chemomab Therapeutics Ltd. stock. As of the latest transaction made, Rhumbline Advisers holds 18,627 shares of CMMB stock, worth $18,068. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,627
Previous 18,627
-0.0%
Holding current value
$18,068
Previous $9,000
55.56%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CMMB
# of Institutions
16Shares Held
2.66MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA2.24MShares$2.17 Million0.04% of portfolio
-
Ikarian Capital, LLC Dallas, TX213KShares$206,9900.02% of portfolio
-
Two Sigma Investments, LP New York, NY40KShares$38,7940.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny37.8KShares$36,6660.0% of portfolio
-
Kestra Private Wealth Services, LLC31.2KShares$30,3030.0% of portfolio
About Chemomab Therapeutics Ltd.
- Ticker CMMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,431,700
- Market Cap $11.1M
- Description
- Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...